Literature DB >> 7246125

On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone.

S P Fällström, B Lindblad, G Steen.   

Abstract

Phenylalanine and homogentisate increase the concentration of succinylacetoacetate and succinylacetone both in serum and urine in patients with hereditary tyrosinemia and therefore increase the excretion of 5-aminolevulinate. Both phenylalanine and homogentisate cause a tubular proteinuria which is in agreement with our hypothesis that their metabolites maleylacetoacetate and fumarylacetoacetate are the toxic compounds in hereditary tyrosinemia. The patient with the highest excretion of succinylacetoacetate and succinylacetone has the slightest tubular proteinuria whereas the one with the lowest excretion of these compounds has the more pronounced tubular proteinuria. It is suggested that this is caused by a difference in the ability to reduce the presumed toxic compounds fumarylacetoacetate and maleylacetoacetate, i.e. the precursors of succinylacetoacetate.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7246125     DOI: 10.1111/j.1651-2227.1981.tb16558.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  7 in total

1.  Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.

Authors:  M Tuchman; D K Freese; H L Sharp; C B Whitley; M L Ramnaraine; R A Ulstrom; J S Najarian; N Ascher; N R Buist; A B Terry
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

2.  Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.

Authors:  S Manabe; S Sassa; A Kappas
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

3.  Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1.

Authors:  M D Bain; P Purkiss; M Jones; P Bingham; T E Stacey; R A Chalmers
Journal:  Eur J Pediatr       Date:  1990-06       Impact factor: 3.183

4.  Visceral pathology of hereditary tyrosinemia type I.

Authors:  P Russo; S O'Regan
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

5.  Treatment adherence in tyrosinemia type 1 patients.

Authors:  Domingo González-Lamuño; Paula Sánchez-Pintos; Fernando Andrade; María L Couce; Luís Aldámiz-Echevarría
Journal:  Orphanet J Rare Dis       Date:  2021-06-03       Impact factor: 4.123

6.  Phenotypic mapping of metabolic profiles using self-organizing maps of high-dimensional mass spectrometry data.

Authors:  Cody R Goodwin; Stacy D Sherrod; Christina C Marasco; Brian O Bachmann; Nicole Schramm-Sapyta; John P Wikswo; John A McLean
Journal:  Anal Chem       Date:  2014-06-10       Impact factor: 6.986

7.  Tyrosinemia type III in an asymptomatic girl.

Authors:  Edyta Szymanska; Malgorzata Sredzinska; Elzbieta Ciara; Dorota Piekutowska-Abramczuk; Rafal Ploski; Dariusz Rokicki; Anna Tylki-Szymanska
Journal:  Mol Genet Metab Rep       Date:  2015-10-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.